UNSPSC 51171726: Zaldaride maleate

This classification denotes an antidiarrheal agent with the molecular formula C26H28N4O2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K7SG01P7NJ, chemically known as 1,3-dihydro-1-(1-((4-methyl-4h,6h-pyrrolo(1,2-a)(4,1)benzoxazepin-4-yl)methyl)-4-piperidinyl)-2h-benzimidazol-2-one maleate, but more generally known as zaldaride maleate, which bears US NIH Compound Identifier 6450522.

European Medicines Agency schedules zaldaride maleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00131MIG. Most nations, for tariff purposes, schedule zaldaride maleate under HS 29349990. SMILES: CC1(C2CCCN2-C3CCCCC3CO1)CN4CCC(CC4)N5C6CCCCC6[NH]C5=O.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51171726 Zaldaride maleate is a Commodity code nominally identifying a specific pharmaceutical active ingredient, but recent state and local solicitation activity under this code does not reflect direct procurement of zaldaride maleate itself. Instead, issuing bodies are using the code to tag broad pharmaceutical and drug-testing service procurement across different operational contexts. The three recent opportunities in the block span offender drug-testing services (specimen collection, immunoassay screening, and confirmatory testing via LC/MS/MS or GC/MS), therapeutic pharmacy initiatives exploring direct-to-manufacturer prescription fulfillment, and cooperative purchasing arrangements for generic multi-source pharmaceuticals and over-the-counter products. This mismatch between the code's nominal scope and actual solicitation content signals that state and local procurement offices may be applying the code as a catch-all pharmaceutical category rather than targeting zaldaride maleate specifically, suggesting limited relevance for vendors supplying the named drug ingredient.

Activity spans Texas, Minnesota, and participating cooperative members. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services, due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026 with three optional one-year renewals. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, functioning as exploratory market intelligence rather than a binding solicitation with award amounts. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with contract effectiveness July 1, 2026.